Impact of residual fluid on treatment outcomes in nAMD

In this episode, my guests Vision Academy and Barometer Program member Professor Jean-François Korobelnik, Professor and Head of the Ophthalmology Department at the University Hospital of Bordeaux in France, and Vision Academy member Professor Robyn Guymer, Deputy Director at the Centre for Eye Research and Professor of Ophthalmic at the University of Melbourne in Australia, discuss considerations for devising flexible and individualized treatment regimens for patients with nAMD with residual fluid.Using examples from their own clinical experience, Professors Korobelnik and Guymer explore the nuanced relationship between efficacy of anti-VEGF treatment and location and presence (or absence) of fluid in patients with nAMD.The Vision Academy Viewpoint providing recommendations for the assessment and monitoring of fluid status can be found on the website, along with other viewpoints and resources. Always refer to local treatment guidelines and relevant prescribing information. Please review the appropriate product information before prescribing.SUBSCRIBE to ‘A Chat with Anat’ to never miss an episode! Further information on content in other podcasts in this series can be found here.                    Speaker disclosures:Professor Jean-François Korobelnik Consultancy: Abbvie, Allergan, Apellis, Bayer, Carl Zeiss Meditec, Janssen, NanoRetina, Roche, and Théa.Professor Robyn GuymerAdvisory boards and/or Consultancy: Apellis, Bayer, Belite Bio, Boehringer Ingelheim Pharmaceuticals, Character Bioscience, Genentech, Novartis, Ocular Therapeutix, and Roche.March 2026 | PP-PF-OPHT-ALL-0161-1Further information on residual fluid:Arnold J.J, et al. The role of sub-retinal fluid in determining treatment outcomes in patients with neovascular age-related macular degeneration - a phase IV randomised clinical trial with ranibizumab: the FLUID study. BMC Ophthalmol. 2016. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4806513/Lek JJ., et al. Interpretation of subretinal fluid using OCT in intermediate age-related macular  degeneration. Ophthalmol Retina. 2018. https://www.sciencedirect.com/science/article/abs/pii/S2468653017307315?via%3Dihub Hahn P, Eliott D, eds. 2021 Global Trends in Retina Survey. 2021. https://www.asrs.org/content/documents/2021-global-trends-survey-highlights.pdf (accessed 2 April 2024).This podcast series is intended for HCPs, and is not intended for UK audiences. Always refer to local treatment guidelines and relevant prescribing information. Please review the product information before prescribing.This podcast series is produced and funded by Bayer. The views and opinions expressed throughout this podcast are the speakers' own, based on their clinical experience and expertise.The Barometer Program is managed by clinical leaders in ophthalmology as well as representatives from the IFA, IAPB and Bayer. The activities of the Barometer Program are funded and facilitated by Bayer where the scientists and representatives from IFA and IAPB retain decision authority to the research scope, methods, analysis of findings, and dissemination of the outputs of the Barometer Program.The Vision Academy is a group of over 80 international experts who, through their collective expertise, provide consensus guidance for managing clinically challenging situations, especially in areas of controversy or with insufficient conclusive evidence. The Vision Academy is funded and facilitated by Bayer. The opinions and guidance of the Vision Academy outputs are those of its members and do not necessarily reflect the opinions of Bayer.